RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $187,818,279 | +0.2% | 24,551,409 | -2.2% | 0.17% | +7.5% |
| Q2 2023 | $187,479,296 | +11.8% | 25,097,630 | -0.2% | 0.16% | +5.3% |
| Q1 2023 | $167,653,985 | -12.4% | 25,135,530 | +1.3% | 0.15% | -24.1% |
| Q4 2022 | $191,368,754 | -16.7% | 24,820,850 | +14.9% | 0.20% | -16.0% |
| Q3 2022 | $229,767,000 | +30.6% | 21,594,693 | -0.1% | 0.24% | +31.7% |
| Q2 2022 | $175,871,000 | +11.7% | 21,605,685 | -1.7% | 0.18% | +63.6% |
| Q1 2022 | $157,388,000 | -58.5% | 21,981,604 | -0.6% | 0.11% | -47.1% |
| Q4 2021 | $378,969,000 | -25.3% | 22,123,155 | +0.3% | 0.21% | -21.8% |
| Q3 2021 | $507,632,000 | -24.9% | 22,061,374 | +19.1% | 0.27% | -19.1% |
| Q2 2021 | $676,017,000 | – | 18,521,000 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |